The shortlist to run the Amazon-Berkshire-JPMorgan healthcare venture

As Berkshire Hathaway’s Warren Buffett has said, one of the first priorities for the highly anticipated healthcare venture between Berkshire, Amazon and JPMorgan is finding a CEO to run it. According to CNBC, two of the three names on their shortlist don’t want the job.

The three names CNBC mentioned were former acting administrator of CMS Andy Slavitt, former U.S. chief technology officer and Castlight Health co-founder Todd Park and Gary Loveman, a former senior executive at Aetna.

Park told CNBC that “while I wish this new endeavor the very best, I am not a candidate to lead it.” Slavitt appeared to tamp down speculation in a tweet, calling the venture “interesting and filled with a lot of promise, but my passion is bringing healthcare to every American and closing the gaps for vulnerable communities & families,” referencing his role in the recently launched group, the United States of Care.

Buffett has said he expects the CEO to be selected this year. CNBC said Berkshire Hathaway’s Todd Combs is leading the search, with an informal role being assumed by venture capitalist John Doerr.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.